# US 2022/0187317 A1 · Biomarkers for diagnosing non-alcoholic steatohepatitis (nash) or hepatocellular carcinoma (hcc)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0187317 A1
- Document ID: US20220187317A1
- Status: Published application
- Kind: A1
- Application number: 17/535,018
- Filed: 2021-11-24
- Published: 2022-06-16
- Earliest claimed: 2020-11-25
- Assignees: Venn Biosciences Corporation
- Applicants: Venn Biosciences Corporation
- Inventors: Prasanna Ramachandran; Gege xu
- Web page: https://patentgrep.com/patent/US20220187317A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 30/7233: {interfaced to liquid or supercritical fluid chromatograph (interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04)}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G06N 3/08: Learning methods
- G06N 3/09: Supervised learning
- G06N 20/00: Machine learning
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/20: Supervised data analysis
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N 2030/027: {Liquid chromatography}
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06N: COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Embodiments described herein generally relate to technologies for analyzing peptide structures for diagnosing and/or treating a disease state advancing through a disease progression. A non-limiting example of a method relating to the technologies described in the subject application may include receiving peptide structure data corresponding to the biological sample obtained from the subject, identifying a peptide structure profile, and diagnosing a disease state within a disease progression. The example may further include generating a diagnosis output relating to the disease state. In at least some cases, the peptide structure profile may include glycosylated peptides, aglycosylated peptides, or both.

## Claims

### Claim 1

A method of classifying a biological sample with respect to a plurality of states associated with fatty liver disease (FLD) progression, the method comprising:
receiving peptide structure data corresponding to a set of glycoproteins in the biological sample obtained from a subject;
inputting quantification data identified from the peptide structure data for a set of peptide structures into a machine learning model, wherein the set of peptide structures includes at least one peptide structure identified from a plurality of peptide structures in Table 1;
analyzing the quantification data using the machine learning model to generate a disease indicator; and
generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing a corresponding state of the plurality of states associated with the FLD progression.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease indicator comprises a score and wherein generating the diagnosis output comprises:
determining that the score falls within a selected range associated with the corresponding state of the plurality of states; and
determining that the biological sample evidences the corresponding state in response to a determination that the score falls within the selected range associated with corresponding state.

### Claim 3 (depends on 1)

The method of claim 1, wherein the plurality of states includes a non-alcoholic steatohepatitis (NASH) state and a hepatocellular carcinoma (HCC) state.

### Claim 4 (depends on 1)

The method of claim 1, wherein the plurality of states includes a non-NASH/HCC state that comprises at least one of a healthy state, a liver disease-free state, or a benign hepatic mass state.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one peptide structure comprises a glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence, as identified in Table 1, with the peptide sequence being one of SEQ ID NOS: 23, 24, 25, 29, 30, 31, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 as defined in Table 1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the quantification data for a peptide structure of the set of peptide structures comprises at least one of an abundance, a relative abundance, a normalized abundance, a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the peptide structure data is generated using multiple reaction monitoring mass spectrometry (MRM-MS).

### Claim 8

A method of training a model to diagnose a subject with one of a plurality of states associated with fatty liver disease (FLD) progression, the method comprising:
receiving quantification data for a panel of peptide structures for a plurality of subjects diagnosed with the plurality of states associated with the FLD progression, wherein the quantification data comprises a plurality of peptide structure profiles for the plurality of subjects and identifies a corresponding state of the plurality of states for each peptide structure profile of the plurality of peptide structure profiles; and
training a machine learning model using the quantification data to determine which state of the plurality of states a biological sample from the subject corresponds.

### Claim 9 (depends on 8)

The method of claim 8, wherein training the machine learning model comprises:
training the machine learning model using a portion of the quantification data corresponding to a set of peptide structures that is a subset of the panel of peptide structures to determine which state of the plurality of states the biological sample from the subject corresponds.

### Claim 10 (depends on 9)

The method of claim 9, further comprising:
performing a differential expression analysis using the quantification data for the plurality of subjects.

### Claim 11 (depends on 10)

The method of claim 10, further comprising:
identifying the set of peptide structures as the subset of the panel of peptide structures relevant to determining which state of the plurality of states the biological sample from the subject corresponds based on at least one of fold-changes, false discovery rates, or p-values computed as part of the differential expression analysis.

### Claim 12 (depends on 8)

The method of claim 8, wherein the plurality of states further includes at least one of a non-alcoholic steatohepatitis (NASH) state, a hepatocellular carcinoma (HCC) state, or a healthy state.

### Claim 13

A method of detecting a presence of one of a plurality of states associated with fatty liver disease (FLD) progression in a biological sample, the method comprising:
receiving peptide structure data corresponding to a set of glycoproteins in the biological sample obtained from a subject;
analyzing the peptide structure data using a supervised machine learning model to generate a disease indicator based on at least 3 peptide structures selected from a group of peptide structures identified in Table 1; and
detecting the presence of a corresponding state of the plurality of states associated with the FLD progression in response to a determination that the disease indicator falls within a selected range associated with the corresponding state.

### Claim 14 (depends on 13)

The method of claim 13, wherein a peptide structure of the at least 3 peptide structures comprises a glycopeptide structure defined by a peptide sequence and a glycan structure linked to the peptide sequence at a linking site of the peptide sequence, as identified in Table 1, with the peptide sequence being one of SEQ ID NOS: 23, 24, 25, 29, 30, 31, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, or 52 as defined in Table 1.

### Claim 15 (depends on 13)

The method of claim 13, wherein the supervised machine learning model comprises a logistic regression model.

### Claim 16 (depends on 13)

The method of claim 13, wherein the supervised machine learning model comprises a penalized multivariable logistic regression model.

### Claim 17 (depends on 13)

The method of claim 13, wherein the peptide structure data comprises quantification data, the quantification data for a peptide structure of the group of peptide structures comprising at least one of an abundance, a relative abundance, a normalized abundance, a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration.

### Claim 18 (depends on 13)

The method of claim 13, wherein the disease indicator is a probability score.

### Claim 19 (depends on 13)

The method of claim 13, further comprising:
generating a report that includes a diagnosis based on the corresponding state detected for the subject.

### Claim 20 (depends on 13)

The method of claim 13, wherein the plurality of states includes at least two selected from a group consisting of a non-alcoholic steatohepatitis (NASH) state, a hepatocellular carcinoma (HCC) state, and a non-NASH/HCC state.
